saquinavir + nelfinavir + stavudine

**saquinavir + nelfinavir + stavudine** is a combination of three antiretroviral agents used in the treatment of HIV infection. - **Saquinavir** and **nelfinavir** are both HIV-1 protease inhibitors; they block the HIV protease enzyme, preventing viral maturation and replication[3][6]. - **Stavudine** is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits the HIV reverse transcriptase enzyme, blocking viral DNA synthesis[3]. This combination has been investigated for salvage therapy in treatment-experienced patients with HIV, especially those who have failed previous regimens with other protease inhibitors. The regimen aims to enhance viral suppression by combining agents with different mechanisms, and in some studies, it has shown additive (sometimes synergistic) antiviral effects, although long-term virologic benefit may be limited by resistance and pharmacokinetic factors[1][2][6]. Developed primarily in the academic and clinical research setting as a response to treatment failure in HIV patients, no unique brand name or commercial product exists for the exact combination.